This trial evaluated the use of the Oncotype DX Breast Recurrence Score® assay against these criteria in 680 women with hormone receptor-positive (HR+), HER2-negative early breast cancer with 1–3 lymph nodes positive (LN+) in the UK National Health Service (NHS). This evidence concerns the gene NR4A1 and breast carcinoma.